Assembly Biosciences, Inc.
ASMB Nasdaq
SEC CIK 1426800
Follow Assembly Biosciences
Weekly email: filings, results
Revenue, last quarter
$3M
−72.6% vs same quarter last year
Net income
−$20.3M
−120.3% vs same quarter last year
EPS, diluted
−$0.93
−29.2% vs same quarter last year
Operating cash flow
−$17.2M
−13.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $72.3M | −$6.1M |
| FY24 | $28.5M | −$40.2M |
| FY23 | $7.2M | −$61.2M |
| FY22 | $0 | −$93.1M |
| FY21 | $6.3M | −$129.9M |
| FY20 | $79.1M | −$62.2M |
| FY19 | $16M | −$97.6M |
| FY18 | $14.8M | −$90.8M |
| FY17 | $9M | −$42.8M |
| FY16 | $0 | −$44.3M |
| FY15 | - | −$28.5M |
| FY14 | - | −$23.8M |
| FY13 | - | −$19.4M |
| FY12 | - | −$24.8M |
| FY11 | - | −$34.3M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −16.8% | −8.5% |
| FY24 | −159.3% | −140.9% |
| FY23 | −902.5% | −854.8% |
| FY22 | - | - |
| FY21 | −2121.7% | −2076.4% |
| FY20 | −81.9% | −78.6% |
| FY19 | −643.4% | −611.6% |
| FY18 | −626.4% | −613% |
| FY17 | −579.1% | −474.7% |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$41.2M |
| FY24 | −$51.1M |
| FY23 | $22.5M |
| FY22 | −$84.6M |
| FY21 | −$96.5M |
| FY20 | −$63.4M |
| FY19 | −$85.6M |
| FY18 | −$65.3M |
| FY17 | $995K |
| FY16 | −$35M |
| FY15 | −$18.8M |
| FY14 | −$15.1M |
| FY13 | −$17.8M |
| FY12 | −$21.4M |
| FY11 | −$25.1M |
- Assembly Biosciences
- Healthcare median
Show the numbers
| Year | Assembly Biosciences | Healthcare median |
|---|---|---|
| FY25 | −8.5% | −30.6% |
| FY24 | −140.9% | −47% |
| FY23 | −854.8% | −58% |
| FY22 | - | −80.4% |
| FY21 | −2076.4% | −71.8% |
| FY20 | −78.6% | −62.2% |
| FY19 | −611.6% | −46.2% |
| FY18 | −613% | −49.6% |
| FY17 | −474.7% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |